Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,070 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa).
Eichler M, Pink D, Menge F, Jakob J, Hentschel L, Richter S, Hohenberger P, Kasper B, Andreou D, Singer S, Grützmann R, Dmytrow DI, Arndt K, Tuchscherer A, Reichardt P, Ahrens M, Kunitz A, Mohm J, Bornhäuser M, Schmitt J, Schuler MK. Eichler M, et al. Among authors: richter s. Eur J Cancer Care (Engl). 2021 Nov;30(6):e13484. doi: 10.1111/ecc.13484. Epub 2021 Aug 3. Eur J Cancer Care (Engl). 2021. PMID: 34342924
Impact of Different Exercise Programs on Severe Fatigue in Patients Undergoing Anticancer Treatment-A Randomized Controlled Trial.
Schuler MK, Hentschel L, Kisel W, Kramer M, Lenz F, Hornemann B, Hoffmann J, Richter S, Ehninger G, Bornhäuser M, Kroschinsky F. Schuler MK, et al. Among authors: richter s. J Pain Symptom Manage. 2017 Jan;53(1):57-66. doi: 10.1016/j.jpainsymman.2016.08.014. Epub 2016 Oct 12. J Pain Symptom Manage. 2017. PMID: 27744016 Free article. Clinical Trial.
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S. Schöffski P, et al. Among authors: richter s. Ann Oncol. 2017 Dec 1;28(12):3000-3008. doi: 10.1093/annonc/mdx527. Ann Oncol. 2017. PMID: 28950372 Free PMC article. Clinical Trial.
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ. Schöffski P, et al. Among authors: richter s. Eur J Cancer. 2018 May;94:156-167. doi: 10.1016/j.ejca.2018.02.011. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29567632 Clinical Trial.
2,070 results